Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

679 - Risk stratification of diffuse large B cell lymphoma using IHC

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

SUNNY Garg

Citation

Annals of Oncology (2015) 26 (suppl_9): 85-92. 10.1093/annonc/mdv526

Authors

S. Garg1, K. Lakshmaiah2, P. Cs3, C.R. Rao3, K. Lokesh3, G. Babu2, S. Babu2, L. D2, L.A. Jacob1, R. Lk2, R. Ah2

Author affiliations

  • 1 Department Of Medical Oncology, Kidwai Memorial Institute of Oncology, 560029 - Bangalore/IN
  • 2 Medical Oncology, Kidwai Memorial Institute of Oncology, 560030 - Bangalore/IN
  • 3 Department Of Pathology, Kidwai Memorial Institute of Oncology, 560029 - Bangalore/IN
More

Resources

Abstract 679

Aim/Background

Risk stratify of the patients of Diffuse Large B Cell Lymphoma (DLBCL) based on germinal centre subtype, Ki 67 and Bcl-2 expression, and IPI scoring and study the prognostic significant of each of these variables. Previous studies are available with conflicting results and there is a paucity of such study from India.

Methods

It is a retrospective study of 112 patients. Ki 67 cutoff of 70% or more was used to classify into high and low. Ki 67 analysis was available for 76 patients and BCL-2 analysis for 96 patients. All patients received treatment with CHOP based chemotherapy. Survival curves were estimated by the Kaplan-Meier analysis, using log-rank test.

Results

Of the total patients, 64 were GCB type and 48 were non-GCB type. The median survival was 34 months in former and 22 months in latter (P = 0.043). Median survival was greater in Bcl-2 negative patients (n = 52) as compared to the positive ones (n = 44) (36 vs 24.5 months, P = 0.003), and was greater in patients with low Ki 67 (n = 32) as compared to high Ki 67 (n = 44) (32 m vs 21.5 m, P = 0.033). Further, subgroup analysis in Ki 67 arm was done based on subtype (GCB or non-GCB) and IPI risk (high or low). In the GCB subtype, low Ki 67 had a better survival as compared to high Ki 67 (35 m vs 28 m, P = 0.044). Whereas, in the non-GCB subtype, the results were same but insignificant (26.5 m vs 18 m, P = 0.7). In the high IPI arm, low Ki 67 had a better survival (26.5 m vs 17 m, P = 0.02), whereas, in low IPI arm, the results were similar but statistically insignificant (39 m vs 38 m, P = 0.837). Similarly, subgroup analysis was done in the Bcl-2 arm based on subtype and IPI risk. In the non-GCB type, patients with Bcl-2 negativity had a survival advantage over the Bcl-2 positive ones (36.5 m vs 17 m, P = 0.02), similarly in the GCB subtype (36 m vs 33 m, P = 0.032). In the high IPI arm, Bcl-2 negativity had a survival advantage (30 m vs 18.5 m, P = 0.002). In the low IPI arm, similar results were obtained (44 vs 39 months, P = 0.037).

Conclusions

GCB subtype, Bcl-2 negativity, and low Ki 67 independently had a survival benefit. Also, the number of patients with low Ki 67 and Bcl-2 negativity were higher in the GCB type, and vice versa. Low Ki 67 had a survival advantage in GCB subtype and high IPI. Bcl-2 negativity had a survival advantage irrespective of GCB and IPI status.

Clinical trial identification

NA

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings